Product Information
ORIAHNN 300-1-0.5 MG/300 MG CAPS is a brand product labeled by AbbVie Inc., priced at $22.0044 per EA under NDC 00074101756. Its NADAC has been published 250 times since Sep 22, 2021.
FDA first approved this application on May 29, 2020.
Manufacturer
AbbVie Inc.NDC
00074101756
Classification
Brand
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
New Drug (NDA)
FDA Application
NDA213388FDA Approved
5/29/2020
On Market Since
5/29/2020
Price Statistics
The NADAC for ORIAHNN 300-1-0.5 MG/300 MG CAPS has been published 250 times since Sep 22, 2021, and over the history we have for it it has risen 30.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $22.0044 per EA |
|---|---|
| All-time high | $22.0044 (Sep 30, 2026) |
| All-time low | $16.8370 (Sep 22, 2021) |
| 52-week high | $22.0044 |
| 52-week low | $20.7116 |
| Median price | $19.6502 |
| Average price | $19.5664 |
| Largest weekly change | +7.4% (Jan 26, 2022) |
| Weeks tracked | 250 |
| Tracking since | Sep 22, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Elagolix and Estradiol and Norethisterone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Elagolix and Estradiol and Norethisterone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ORIAHNN 300-1-0.5 MG/300 MG CAPS?
The current National Average Drug Acquisition Cost (NADAC) for ORIAHNN 300-1-0.5 MG/300 MG CAPS, manufactured by AbbVie Inc., is $22.0044 per EA (NDC 00074101756), effective Sep 30, 2026.
How has the price of ORIAHNN 300-1-0.5 MG/300 MG CAPS changed over time?
Over the history we have for it, the NADAC for ORIAHNN 300-1-0.5 MG/300 MG CAPS has risen 30.7%. It has been tracked across 250 weekly CMS publications since Sep 22, 2021.
What are the highest and lowest recorded NADAC prices for ORIAHNN 300-1-0.5 MG/300 MG CAPS?
Since Sep 22, 2021, the NADAC for ORIAHNN 300-1-0.5 MG/300 MG CAPS has ranged from a low of $16.8370 (Sep 22, 2021) to a high of $22.0044 (Sep 30, 2026), with a median of $19.6502 per EA.
Are there cheaper alternatives to ORIAHNN 300-1-0.5 MG/300 MG CAPS?
No other NADAC-published product currently shares the active ingredient and strength of ORIAHNN 300-1-0.5 MG/300 MG CAPS in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ORIAHNN 300-1-0.5 MG/300 MG CAPS?
ORIAHNN 300-1-0.5 MG/300 MG CAPS (NDC 00074101756) is labeled by AbbVie Inc., and CMS classifies it as a brand product.